As expected, the European Commission approves Jazz Pharmaceuticals’ (NASDAQ:JAZZ) Sunosi (solriamfetol) to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with narcolepsy (with or without cataplexy) or obstructive sleep apnea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure.
Two months ago, the advisory group CHMP adopted a positive opinion backing approval.
The company in-licensed the dual-acting dopamine and norepinephrine reuptake inhibitor from Aerial Biopharma LLC in 2014.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.